Bicara Therapeutics (BCAX) Profit After Tax (2023 - 2026)

Bicara Therapeutics' Profit After Tax history runs 4 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 52.56% year-over-year to -$56.2 million in Q1 2026; TTM through Mar 2026 was -$119.7 million, a 59.9% decrease from a year earlier, with the FY2025 full-year figure at $243000.0, up 100.36% from the prior year.
• Profit After Tax slipped to -$56.2 million in Q1 2026 per BCAX's latest filing, from $379000.0 in the prior quarter.
• Across five years, Profit After Tax topped out at $379000.0 in Q4 2025 and bottomed at -$56.2 million in Q1 2026.
• The 4-year median for Profit After Tax is -$21.9 million (2023), against an average of -$24.2 million.
• Biggest YoY gain for Profit After Tax was 101.81% in 2025; the steepest drop was 194.58% in 2025.
• Year by year, Profit After Tax stood at -$12.4 million in 2023, then plunged by 68.46% to -$21.0 million in 2024, then soared by 101.81% to $379000.0 in 2025, then sank by 14931.4% to -$56.2 million in 2026.
• Per Business Quant, the three latest BCAX Profit After Tax figures stand at -$56.2 million (Q1 2026), $379000.0 (Q4 2025), and -$36.5 million (Q3 2025).